Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice

Bo Jian Zheng; Mun Hon Ng; Li Fang He; Xin Yao; Kwok Wah Chan; Kwok Yung Yuen; Yu Mei Wen

doi:10.1016/S0264-410X(01)00158-X

Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice

Bo Jian Zheng, Mun Hon Ng, Li Fang He, Xin Yao, Kwok Wah Chan, Kwok Yung Yuen, Yu Mei Wen

Research output: Contribution to journal › Article › peer-review

56 Citations (Scopus)

Abstract

Therapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways.

Original language	English
Pages (from-to)	4219-4225
Number of pages	7
Journal	Vaccine
Volume	19
Issue number	30
DOIs	https://doi.org/10.1016/S0264-410X(01)00158-X
Publication status	Published - Jul 20 2001
Externally published	Yes

ASJC Scopus Subject Areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Keywords

Hepatitis B virus
Immune tolerance
Therapeutic vaccine

Access to Document

10.1016/S0264-410X(01)00158-X

Cite this

@article{d5fd2292bf584d368f7b7aa37a612e9d,

title = "Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice",

abstract = "Therapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways.",

keywords = "Hepatitis B virus, Immune tolerance, Therapeutic vaccine",

author = "Zheng, {Bo Jian} and Ng, {Mun Hon} and He, {Li Fang} and Xin Yao and Chan, {Kwok Wah} and Yuen, {Kwok Yung} and Wen, {Yu Mei}",

year = "2001",

month = jul,

day = "20",

doi = "10.1016/S0264-410X(01)00158-X",

language = "English",

volume = "19",

pages = "4219--4225",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier B.V.",

number = "30",

}

TY - JOUR

T1 - Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice

AU - Zheng, Bo Jian

AU - Ng, Mun Hon

AU - He, Li Fang

AU - Yao, Xin

AU - Chan, Kwok Wah

AU - Yuen, Kwok Yung

AU - Wen, Yu Mei

PY - 2001/7/20

Y1 - 2001/7/20

N2 - Therapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways.

AB - Therapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways.

KW - Hepatitis B virus

KW - Immune tolerance

KW - Therapeutic vaccine

UR - http://www.scopus.com/inward/record.url?scp=0035919599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035919599&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(01)00158-X

DO - 10.1016/S0264-410X(01)00158-X

M3 - Article

C2 - 11457548

AN - SCOPUS:0035919599

SN - 0264-410X

VL - 19

SP - 4219

EP - 4225

JO - Vaccine

JF - Vaccine

IS - 30

ER -

Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice

Abstract

ASJC Scopus Subject Areas

Keywords

Access to Document

Other files and links

Cite this